• Pilar García Alfonso, Andrés Muñoz Martin, Sonsoles Alvarez Suarez, Monserrat Blanco Codeidido, Rebeca Mondejar Solis, Gonzalo Tapia Rico, Pilar López Martín, and Miguel Martin.
• Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain. pgarcaalfonso@gmail.com
• Onkologie. 2013 Jan 1; 36 (6): 363-7.

BackgroundAlthough phase III studies have investigated the effect of adding bevacizumab to the 3-weekly capecitabine plus irinotecan (XELIRI) combination in the first-line treatment of metastatic colorectal cancer (mCRC), no phase III studies investigating the effects of adding bevacizumab to biweekly XELIRI have been published.Patients And MethodsA retrospective pooled analysis of 2 single-arm phase II studies was performed. Previously untreated patients with mCRC received irinotecan 175 mg/m(2) on day 1 followed by capecitabine 1,000 mg/m(2) twice daily on days 2-8 every 2 weeks with or without bevacizumab 5 mg/kg on day 1.ResultsIn total, 53 patients received XELIRI, and 46 patients received XELIRI plus bevacizumab. There was a statistically significant increase in partial response rate with XELIRI plus bevacizumab (63 vs. 26% for XELIRI; p = 0.0002) and overall response rate (67 vs. 32%; p = 0.0005). Median time to disease progression was significantly longer with XELIRI plus bevacizumab (12.3 vs. 9.0 months for XELIRI; p = 0.012); median overall survival did not differ significantly between treatments (23.7 vs. 19.3 months; p = 0.4997). The proportion of patients experiencing at least 1 grade 3/4 adverse event was similar with both treatments (XELIRI, 47%; XELIRI plus bevacizumab, 44%).ConclusionThis retrospective pooled analysis suggests that XELIRI plus bevacizumab has an acceptable tolerability profile and improves efficacy outcomes compared with XELIRI in the first-line treatment of mCRC.© 2013 S. Karger GmbH, Freiburg.

34 keywords...

hide…